|
Back to Home » June 2019 News » MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML) |
MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML) |
June 22, 2019
SAN DIEGO, June 22, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b study of investigational...
Source URL: https://www.prnewswire.com:443/news-releases/mei-pharma-presents-updated-clinical-data-from-the-me-401-phase-1b-study-in-patients-with-indolent-b-cell-malignancies-at-the-2019-international-conference-on-malignant-lymphoma-icml-300872982.html
|
|
|
|
